The role of mtor inhibition in the control of autosomal dominant polycystic kidney disease

Research output: Contribution to journalArticle

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most common type of genetic kidney disease, affects more than 12 million people worldwide. Effective therapies for ADPKD are desperately needed. Persistent progress has been made in the understanding of processes that are responsible for renal cyst formation and progression of ADPKD. Cellular pathways that involve polycystins, intracellular calcium and cAMP regulation, and the serine/threonine-protein kinase mTOR (mammalian target of rapamycin) pathway have been characterized. The understanding of the ADPKD phenotype at the cellular level and the encouraging results in experimental models of polycystic kidney disease have laid the foundation for the development of clinical trials and potentially effective targeted treatments. This review addresses the current knowledge about the pathogenesis of the disease and the overwhelming evidence in support of mTOR as a common molecular pathway for cystogenesis. The recent advances and challenges in understanding the role of mTOR inhibitors in controlling ADPKD in animal models and clinical trials will be discussed.

Original languageEnglish
Pages (from-to)929-938
Number of pages10
JournalDrugs of the Future
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Autosomal Dominant Polycystic Kidney
Sirolimus
TRPP Cation Channels
Clinical Trials
Polycystic Kidney Diseases
Inborn Genetic Diseases
Protein-Serine-Threonine Kinases
Kidney Diseases
Cysts
Theoretical Models
Animal Models
Calcium
Phenotype
Kidney

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The role of mtor inhibition in the control of autosomal dominant polycystic kidney disease. / Perico, Norberto; Remuzzi, G.

In: Drugs of the Future, Vol. 35, No. 11, 11.2010, p. 929-938.

Research output: Contribution to journalArticle

@article{66aaca8576304fb2860afadb3f9afd3d,
title = "The role of mtor inhibition in the control of autosomal dominant polycystic kidney disease",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD), the most common type of genetic kidney disease, affects more than 12 million people worldwide. Effective therapies for ADPKD are desperately needed. Persistent progress has been made in the understanding of processes that are responsible for renal cyst formation and progression of ADPKD. Cellular pathways that involve polycystins, intracellular calcium and cAMP regulation, and the serine/threonine-protein kinase mTOR (mammalian target of rapamycin) pathway have been characterized. The understanding of the ADPKD phenotype at the cellular level and the encouraging results in experimental models of polycystic kidney disease have laid the foundation for the development of clinical trials and potentially effective targeted treatments. This review addresses the current knowledge about the pathogenesis of the disease and the overwhelming evidence in support of mTOR as a common molecular pathway for cystogenesis. The recent advances and challenges in understanding the role of mTOR inhibitors in controlling ADPKD in animal models and clinical trials will be discussed.",
author = "Norberto Perico and G. Remuzzi",
year = "2010",
month = "11",
doi = "10.1358/dof.2010.35.11.1540665",
language = "English",
volume = "35",
pages = "929--938",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - The role of mtor inhibition in the control of autosomal dominant polycystic kidney disease

AU - Perico, Norberto

AU - Remuzzi, G.

PY - 2010/11

Y1 - 2010/11

N2 - Autosomal dominant polycystic kidney disease (ADPKD), the most common type of genetic kidney disease, affects more than 12 million people worldwide. Effective therapies for ADPKD are desperately needed. Persistent progress has been made in the understanding of processes that are responsible for renal cyst formation and progression of ADPKD. Cellular pathways that involve polycystins, intracellular calcium and cAMP regulation, and the serine/threonine-protein kinase mTOR (mammalian target of rapamycin) pathway have been characterized. The understanding of the ADPKD phenotype at the cellular level and the encouraging results in experimental models of polycystic kidney disease have laid the foundation for the development of clinical trials and potentially effective targeted treatments. This review addresses the current knowledge about the pathogenesis of the disease and the overwhelming evidence in support of mTOR as a common molecular pathway for cystogenesis. The recent advances and challenges in understanding the role of mTOR inhibitors in controlling ADPKD in animal models and clinical trials will be discussed.

AB - Autosomal dominant polycystic kidney disease (ADPKD), the most common type of genetic kidney disease, affects more than 12 million people worldwide. Effective therapies for ADPKD are desperately needed. Persistent progress has been made in the understanding of processes that are responsible for renal cyst formation and progression of ADPKD. Cellular pathways that involve polycystins, intracellular calcium and cAMP regulation, and the serine/threonine-protein kinase mTOR (mammalian target of rapamycin) pathway have been characterized. The understanding of the ADPKD phenotype at the cellular level and the encouraging results in experimental models of polycystic kidney disease have laid the foundation for the development of clinical trials and potentially effective targeted treatments. This review addresses the current knowledge about the pathogenesis of the disease and the overwhelming evidence in support of mTOR as a common molecular pathway for cystogenesis. The recent advances and challenges in understanding the role of mTOR inhibitors in controlling ADPKD in animal models and clinical trials will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=79956224909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956224909&partnerID=8YFLogxK

U2 - 10.1358/dof.2010.35.11.1540665

DO - 10.1358/dof.2010.35.11.1540665

M3 - Article

AN - SCOPUS:79956224909

VL - 35

SP - 929

EP - 938

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 11

ER -